The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

The correct diagnosis of anterior optic neuritis was made based on the correlation of onset of decreased vision, pain on EOM testing, presence of an APD, decreased color vision and red desaturation, ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ACUITY ...